| Not Yet Recruiting | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. NCT07389239 | University of Chicago | Phase 1 / Phase 2 |
| Not Yet Recruiting | Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden NCT07459920 | National Cancer Institute, Naples | Phase 2 |
| Recruiting | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patie NCT07262164 | Shanghai Virogin Biotech Co., Ltd. | Phase 1 |
| Recruiting | A Study of MHB009C in Patients With Advanced Solid Tumors NCT07326488 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of JSKN027 in Patients With Advanced Solid Tumors NCT07391644 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 |
| Recruiting | A First in Human Study of PLT012 in Participants With Solid Tumor Cancers NCT07337525 | Pilatus Biosciences Inc | Phase 1 |
| Recruiting | A Study of MHB048C in Patients With Advanced Solid Tumors NCT07192120 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 / Phase 2 |
| Recruiting | An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors NCT07293754 | Repertoire Immune Medicines | Phase 1 / Phase 2 |
| Recruiting | A Study of MHB042C in Patients With Advanced Solid Tumors NCT07192107 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant S NCT07130383 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 2 |
| Recruiting | A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors NCT07126665 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer NCT07110363 | Biotroy Therapeutics | Phase 1 |
| Not Yet Recruiting | Phase I/II Study of SCTB39G in Advanced Solid Tumours NCT07077252 | Sinocelltech Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours NCT07050641 | Sinocelltech Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced So NCT06713148 | Fudan University | EARLY_Phase 1 |
| Recruiting | A Study of MHB118C Injection in Patients With Advanced Solid Tumors NCT07045454 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 |
| Recruiting | Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Sol NCT06718946 | Fudan University | EARLY_Phase 1 |
| Recruiting | A Study of MT027 in Patients with Pleural Malignant Tumors NCT06726564 | Suzhou Maximum Bio-tech Co., Ltd. | Phase 1 |
| Recruiting | To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors NCT06592417 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 NCT06166472 | Akeso | Phase 1 |
| Active Not Recruiting | Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors NCT06150183 | BioNTech SE | Phase 1 |
| Unknown | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 i NCT05911984 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patie NCT05477849 | Shanghai Virogin Biotech Co., Ltd. | Phase 1 |
| Unknown | A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. NCT05396339 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1 / Phase 2 |
| Terminated | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors NCT05098405 | Molecular Partners AG | Phase 1 |
| Unknown | Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors NCT04758897 | CNBG-Virogin Biotech (Shanghai) Ltd. | Phase 1 |
| Unknown | Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With So NCT04864379 | Sir Run Run Shaw Hospital | Phase 1 |
| Unknown | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets NCT04275050 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Terminated | A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Modera NCT04241835 | Epizyme, Inc. | Phase 1 |
| Recruiting | Plasmodium Immunotherapy for Advanced Malignant Solid Tumors NCT04165590 | CAS Lamvac Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor NCT03662815 | Sir Run Run Shaw Hospital | Phase 1 |
| Unknown | Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors NCT03171220 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1 / Phase 2 |